BR112022003884A2 - Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii - Google Patents

Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii

Info

Publication number
BR112022003884A2
BR112022003884A2 BR112022003884A BR112022003884A BR112022003884A2 BR 112022003884 A2 BR112022003884 A2 BR 112022003884A2 BR 112022003884 A BR112022003884 A BR 112022003884A BR 112022003884 A BR112022003884 A BR 112022003884A BR 112022003884 A2 BR112022003884 A2 BR 112022003884A2
Authority
BR
Brazil
Prior art keywords
disorder
liver disease
treatment
actii
receptor antagonists
Prior art date
Application number
BR112022003884A
Other languages
English (en)
Inventor
Daniel Meyers C
Estelle Trifilieff
Laura Coleman
Ronenn Roubenoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022003884A2 publication Critical patent/BR112022003884A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii. a presente divulgação fornece um antagonista do actrii, por exemplo, o antagonista dos actriia e/ou actriib, por exemplo, um anticorpo antirreceptor actrii ou fragmento de ligação ao antígeno do mesmo, por exemplo, bimagrumab, para tratar ou prevenir doença ou distúrbio hepático em um indivíduo em necessidade do mesmo. a presente divulgação também se refere a combinações farmacêuticas compreendendo esses antagonistas do actrii e pelo menos um agente terapêutico adicional no tratamento ou prevenção de doença ou distúrbio hepático.
BR112022003884A 2019-09-03 2020-09-01 Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii BR112022003884A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962895107P 2019-09-03 2019-09-03
PCT/IB2020/058114 WO2021044287A1 (en) 2019-09-03 2020-09-01 Treatment of liver disease or disorder comprising actrii receptor antagonists

Publications (1)

Publication Number Publication Date
BR112022003884A2 true BR112022003884A2 (pt) 2022-05-31

Family

ID=72422213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003884A BR112022003884A2 (pt) 2019-09-03 2020-09-01 Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii

Country Status (12)

Country Link
US (1) US20220340668A1 (pt)
EP (1) EP4025248A1 (pt)
JP (1) JP2022547452A (pt)
KR (1) KR20220054608A (pt)
CN (1) CN114630681A (pt)
AU (1) AU2020341135A1 (pt)
BR (1) BR112022003884A2 (pt)
CA (1) CA3153062A1 (pt)
IL (1) IL290852A (pt)
JO (1) JOP20220057A1 (pt)
MX (1) MX2022002636A (pt)
WO (1) WO2021044287A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2024044782A1 (en) 2022-08-26 2024-02-29 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
CN117577330B (zh) * 2024-01-15 2024-04-02 北京大学 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1075272B1 (en) 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
SI2424895T1 (en) 2009-04-27 2018-01-31 Novartis Ag Ingredients and procedures for increasing muscle growth
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
KR101438265B1 (ko) * 2011-04-04 2014-09-05 한국생명공학연구원 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
CA2942403A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
RU2706007C2 (ru) 2014-11-21 2019-11-13 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
SG11201704770YA (en) 2014-12-22 2017-07-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
WO2017078928A1 (en) 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
WO2017143134A1 (en) 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
AU2017222526A1 (en) 2016-02-22 2018-08-23 Acceleron Pharma Inc. ActRII antagonists for use in increasing immune activity
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10183872B2 (en) 2016-06-13 2019-01-22 Qi Wang Counter circulating liquid processing system by repeatedly re-using thermal energy
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
KR20190056436A (ko) 2016-10-04 2019-05-24 이난타 파마슈티칼스, 인코포레이티드 Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
WO2018133730A1 (zh) 2017-01-20 2018-07-26 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
WO2018190643A1 (en) 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
CA3064794A1 (en) 2017-05-26 2018-11-29 Medshine Discovery Inc. Lactam compound as fxr receptor agonist
MX2020000268A (es) 2017-07-06 2020-07-22 Xuanzhu Biopharmaceutical Co Ltd Agonista de fxr.
CN109053751A (zh) 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂

Also Published As

Publication number Publication date
JOP20220057A1 (ar) 2023-01-30
MX2022002636A (es) 2022-03-25
US20220340668A1 (en) 2022-10-27
CA3153062A1 (en) 2021-03-11
JP2022547452A (ja) 2022-11-14
KR20220054608A (ko) 2022-05-03
CN114630681A (zh) 2022-06-14
IL290852A (en) 2022-04-01
EP4025248A1 (en) 2022-07-13
WO2021044287A1 (en) 2021-03-11
AU2020341135A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
BR112022003884A2 (pt) Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
EA201892218A1 (ru) Способы ингибирования ангиогенеза у пациента
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
BR112018008918A2 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
BR112019006642A2 (pt) antagonistas multiméricos de e-selectina altamente potentes
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
EA201790174A1 (ru) Антипролиферативные соединения и способы их применения
BR112019003989A2 (pt) métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
WO2017106810A3 (en) Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
BR112018007703A2 (pt) anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
BR112021017616A2 (pt) Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
EA201591423A1 (ru) Введение антитела к активину-а пациентам
EA201990988A1 (ru) Антитела против chikv и пути их применения